Decongestion Guided By VExUS Score Or Lung Ultrasound For Renal Recovery In Patients With Cardiorenal Syndrome Type -1
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: frusemide.
- Who it may be relevant to
- Registry conditions: Cardiorenal Syndrome Type 1. Basic parameters: 18 years — 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Evaluation of Decongestion Guided By VExUS Score Or Lung Ultrasound For Renal Recovery In Patients With Cardiorenal Syndrome Type-1 : a Randomized Controlled Trial
Overview
the goal of this observational study is to evaluate the role of VEXUS score and lung ultrasound to guide decongestive therapy in patients with cardiorenal syndrome type -1. the main question it aims to answer is: Can the VEXUS score and lung ultrasound guide the efffect of decongestive therapy on KFR and decongestion metrics in patients with CRS-1 compared to standard assesment ?
Interventions
- Drug frusemide
in this group we use vexus score to asses decongestion in comparison to lung ultrasound in other group
Primary outcome measures
- assesment of KFR using the KDIGO AKI staging improvement [Time frame: 1 week]
Secondary outcome measures (1)
- VEXUS score [Time frame: 48 hours]
Eligibility criteria
Inclusion criteria
- • Patients of both genders aged 18-65 years old.
- Patients with CRS1 criteria (worsening of renal function due to acute heart failure manifested by : ( Dyspnea , orthopnea ,hypoxia , congested neck veins , oliguria and congestion in imaging.)
- Patients with Modified lung ultrasound score(LUSS) more than 15.
Exclusion criteria
- • Refusal to participate.
- Patients with renal transplantation.
- Unknowing baseline creatinine.
- Patients with a life-threatening indication of RRT (defined as intractable hyperkalemia, acidosis, uremic symptoms) at enrollment,
- RRT before recruitment,
- known prehospitalization advanced chronic kidney disease (defined by an estimated GFR <30 mL/min/1.73 m2 or chronic RRT),
- use of extracorporeal membrane oxygenation (ECMO),
- diagnosis of hepatic cirrhosis or other condition with portal hypertension
- Or postrenal causes of AKI
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Asmaa Shahat Mohamedy Behairy — Cairo
Identifiers
NCT: NCT06786728 · MD8.1.2024